H.R. 6227 · 118th Congress (2023–2025)
Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023
This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.
Show official title
To amend the Federal Food, Drug, and Cosmetic Act to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.
Expired in House committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to Health
This bill’s path
This is H.R. 6227’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
Expired
- Sponsor
- Rep. David Schweikert (R-AZ-1)
- Cosponsors
35 cosponsors
13 original · 22 later
21 R · 14 D
- Rep. Kelly Armstrong (R-ND)· Original · Nov 3, 2023
- Rep. Michael C. Burgess (R-TX-26)· Original · Nov 3, 2023
- Rep. Jim Costa (D-CA-21)· Original · Nov 3, 2023
- Rep. Juan Ciscomani (R-AZ-6)· Original · Nov 3, 2023
- Rep. Yadira Caraveo (D-CO-8)· Original · Nov 3, 2023
- Rep. Monica De La Cruz (R-TX-15)· Original · Nov 3, 2023
- Rep. Raúl M. Grijalva (D-AZ-7)· Original · Nov 3, 2023
- Rep. Ruben Gallego (D-AZ-3)· Original · Nov 3, 2023
- Rep. Mike Levin (D-CA-49)· Original · Nov 3, 2023
- Rep. Kevin McCarthy (R-CA-20)· Original · Nov 3, 2023
- Rep. Michelle Steel (R-CA-45)· Original · Nov 3, 2023
- Rep. Keith Self (R-TX-3)· Original · Nov 3, 2023
- Rep. David G. Valadao (R-CA-22)· Original · Nov 3, 2023
- Rep. Debbie Lesko (R-AZ-8)· Later · Nov 8, 2023
- Rep. Doug LaMalfa (R-CA-1)· Later · Nov 29, 2023
- Rep. Brittany Pettersen (D-CO-7)· Later · Nov 29, 2023
- Rep. Eric Swalwell (D-CA-14)· Later · Nov 29, 2023
- Rep. Melanie A. Stansbury (D-NM-1)· Later · Nov 29, 2023
- Rep. Jay Obernolte (R-CA-23)· Later · Dec 4, 2023
- Rep. Scott H. Peters (D-CA-50)· Later · Dec 5, 2023
- Rep. John Joyce (R-PA-13)· Later · Dec 13, 2023
- Rep. Kevin Mullin (D-CA-15)· Later · Dec 13, 2023
- Rep. Lizzie Fletcher (D-TX-7)· Later · Dec 19, 2023
- Rep. Susie Lee (D-NV-3)· Later · Dec 19, 2023
- Rep. Blake D. Moore (R-UT-1)· Later · Dec 19, 2023
- Rep. Mariannette Miller-Meeks (R-IA-1)· Later · Dec 19, 2023
- Rep. Stephanie I. Bice (R-OK-5)· Later · Jan 11, 2024
- Rep. Teresa Leger Fernandez (D-NM-3)· Later · Jan 11, 2024
- Rep. August Pfluger (R-TX-11)· Later · Feb 5, 2024
- Rep. Larry Bucshon (R-IN-8)· Later · Feb 23, 2024
- Rep. Troy Balderson (R-OH-12)· Later · Feb 23, 2024
- Rep. Andrea Salinas (D-OR-6)· Later · Feb 23, 2024
- Rep. Dan Crenshaw (R-TX-2)· Later · Mar 13, 2024
- Rep. Diana Harshbarger (R-TN-1)· Later · Mar 13, 2024
- Rep. Vince Fong (R-CA-20)· Later · Jul 22, 2024
- Policy area
- Health
- Subjects
- Cardiovascular and respiratory health
- Drug safety, medical device, and laboratory regulation
- Health promotion and preventive care
- Prescription drugs
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
▸ 2 committee actions · Nov 3, 2023 – Nov 10, 2023
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Expired
Introduced → Referred to House Health → No further action before the 118th Congress ended.
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (2)
Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023
Display title, Short title · Introduced in House
To amend the Federal Food, Drug, and Cosmetic Act to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.
Official title · Introduced in House